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Abstract
Background: Liaison critical paths (LCPs) for coronary artery dis-
ease (CAD) were developed to support collaborative care for CAD 
patients between cardiologists in emergency hospitals and referring 
physicians through sharing of medical information, including car-
dioprotective medications and cardiovascular risk factors. Howev-
er, little is known about the effects of LCPs in practice.
Methods: We conducted an observational study of CAD patients 
undergoing percutaneous coronary intervention in our hospital be-
tween September 2007 and June 2010; these patients were man-
aged with an LCP by referring physicians after discharge. We sur-
veyed implementation of scheduled hospital visits, prescription of 
cardioprotective medicines, and risk factor measurements 6 and 12 
months after discharge.
Results: Implementation rate of hospital visits was significantly 
elevated  from  50.7%  to  89.3%  after  establishing  LCPs. At  the 
12-month visit, prescription rates for anti-platelet drugs, statins, 
β-blockers, and angiotensin-converting enzyme inhibitors or an-
giotensin II type I receptor blockers were 99.7%, 95.0%, 77.1%, 
and 74.3%, respectively. Target achievement rates for low-density 
lipoprotein cholesterol (LDL-C; < 100 mg/dL) and high-density li-
poprotein cholesterol (HDL-C; ≥ 40 mg/dL) significantly increased 
from 48.6% to 64.5% and 62.0% to 82.7%, respectively, while 
those for body mass index (BMI; < 25 kg/m2), blood pressure (< 
130/80 mmHg), triglycerides (< 150 mg/dL), and HbA1c (< 7.0 %) 
were unchanged. BMI, triglycerides, HDL-C, LDL-C, and HbA1c 
levels significantly improved in patients who implemented all vis-
its. Moreover, risk factor management did not differ significantly 
between cardiologists and non-cardiologists using LCPs.
Conclusions:  LCPs  for  CAD  may  facilitate  implementation  of 
optimal medical therapy and target achievement of risk factors in 
practice.
Keywords: Liaison critical path; Coronary artery disease; Cardio-
vascular prevention; Risk factors; Clinical practice
Introduction
Current guidelines have documented the significance of sys-
temic therapies that reduce plaque vulnerability through ev-
idence-based use of medication and aggressive intervention 
for multiple cardiovascular risk factors in reducing the rate of 
death or myocardial infarction [1-3]. The Clinical Outcomes 
Utilizing Revascularization and Aggressive Drug Evaluation 
(COURAGE) trial demonstrated that focal therapy with per-
cutaneous coronary intervention (PCI) for stenotic coronary 
lesions did not reduce the risk of major cardiovascular events 
when added to optimal medical therapy (OMT) in patients 
with stable coronary artery disease (CAD). This provides ev-
idence reinforcing current guidelines supporting the aggres-
sive use of OMT [4]. However, in clinical practice, almost a 
third of patients are not treated with OMT at discharge fol-
lowing PCI, a pattern that has showed little change even after 
the publication of the COURAGE trial [5]. These findings 
indicate that improvements are required in the incorporation 
of OMT into routine practice. 
In Japan, elderly people over the age of 65 years ac-
counted for 21% of the population, the world’s highest, in 
2005. This percentage increased to 23.2% in June 2011, and 
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is expected to rise further in the future [6]. To reduce the 
load on physicians in emergency hospitals, the government 
has recommended the development of local collaborations 
between emergency hospitals and general clinics since 2006. 
According to this policy, recently stabilized patients with 
CAD tend to be managed by referring primary physicians; 
however, these doctors are not always familiar with recent 
evidence for cardiovascular prevention. To resolve this so-
cial issue, liaison critical paths (LCPs) for the management 
of CAD have been developed. Generally, in the LCP system, 
cardiologists  in  emergency  hospitals  and  referring  physi-
cians cooperatively manage CAD patients using an informa-
tion tool, i.e., printed information sheets or electronic files on 
the internet, to share medical information, including severity 
of CAD, coronary intervention, medications, cardiovascular 
risk factors, guideline-based targets for the control of risk 
factors, and schedules of follow-up examinations. Our hos-
pital is in Kure City, where the elderly account for 28.2% 
of the population [7]; this was Japan’s highest elderly ratio 
in cities with a population of over 150,000 people in 2010. 
A hospital-based LCP system for CAD has been established 
in our hospital since 2007. Recently, in many medical areas, 
public health centers or medical associations have developed 
community-based LCPs for CAD, although the management 
systems  and/or  information  tools  are  somewhat  different 
among medical areas. However, little is known about the 
clinical benefits of LCP in practice.
To assess whether LCP for CAD may have the poten-
tial to facilitate the implementation of OMT, we surveyed 
the  implementation  rate  of  scheduled  hospital  visits,  the 
prescription  rate  of  cardioprotective  medications,  and  the 
achievement rate of guideline targets for risk factors in pa-
tients  managed  with  LCP  for  CAD  before  discharge  and 
during 1 year of observation. In addition, we compared the 
Table 1. Baseline Characteristics of the Subjects
# Statistical analyses were performed by Student’s t-test or chi-square test (*). LCP, liaison critical path; AMI, acute myocardial 
infarction; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.
Without LCP With LCP
P#
(Jan.-Dec. 2006) (Oct. 2007-Jun. 2010)
Number of patients 140 318
Age (y) 70.8 ± 9.3 69.2 ± 9.9 0.093 
Male (%) 66.4 74.2 0.088*
Coronary artery disease
AMI (%) 29.3 28.9 0.939*
Others (%) 70.7 71.1
BMI (kg/m2) 23.3 ± 3.7 24.1 ± 4.0 0.089 
Blood Pressure
Systolic (mmHg) 133.4 ± 25.3 129.4 ± 20.1 0.058 
Diastolic (mmHg) 72.6 ± 15.4 72.8 ± 12.7 0.999 
Laboratory
Triglycerides (mg/dL) 118.5 ± 79.3 125.7 ± 72.2 0.357 
HDL-C (mg/dL) 44.4 ± 13.1 44.4 ± 11.7 0.900 
LDL-C (mg/dL) 100.7 ± 32.3 104.1 ± 30.3 0.291 
HbA1c (%) 6.7 ± 1.6 6.3 ± 1.3 < 0.001
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management of risk factors by referring physicians using the 
LCP system between cardiologists and non-cardiologists.
Methods
Management system using liaison critical path for CAD
We established an LCP system for the management of pa-
tients with CAD in routine practice. This system was intro-
duced to all patients with CAD undergoing PCI who received 
outpatient treatment in general clinics after discharge. Using 
this system, all patients received multidisciplinary education 
on  preventing  cardiovascular  events  before  discharge,  in-
cluding information on their cardiovascular risk factors, the 
purpose and effects of their medication, and how to change 
their lifestyle, i.e., how to make healthy food choices and 
do suitable exercise. All of this information was described 
on the LCP information sheet. Furthermore, the LCP infor-
mation sheet provided each patient’s personal medical infor-
mation to referring physicians in general clinics, including 
severity of CAD, coronary intervention, medications, car-
Table 2. Implementation of Follow-up Hospital Visits With or Without Liaison Critical Path
# Statistical analyses were performed by chi-square test. LCP, liaison critical path.
Figure 1. Prescription of several classes of cardioprotective medicines in clinical practice with 
liaison critical path. Proportions of the patients who were prescribed anti-platelet agents, statins, 
β-blockers,  angiotensin-converting  enzyme  inhibitors  (ACE-Is)/angiotensin  II  type  I  receptor 
blockers (ARBs), and calcium channel (Ca) blockers are shown at indicated times. Six-month 
(6M) and 12-month (12M) visits were scheduled at 6 ± 3 months and 12 ± 3 months after hospital 
discharge, respectively. Statistical analyses were performed by chi-square test. #: P < 0.05 vs. 
on discharge.
Without LCP With LCP
P#
(Jan.-Dec. 2006) (Oct. 2007-Jun. 2010)
Total subjects, n 140 318
6-month visit, n (%) 75 (53.6) 280 (88.1) < 0.001
12-month visit, n (%) 71 (50.7) 284 (89.3) < 0.001
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diovascular risk factors, the guideline targets for risk fac-
tors, and schedules of follow-up examinations in our hospi-
tal. Official staff assigned to local clinical liaison sent a list 
of patients to referring physicians by fax or e-mail to remind 
them which patients were scheduled to visit our hospital be-
fore the scheduled follow-up date. Trained nurses explained 
the follow-up examinations to patients before the scheduled 
date by phone. Referring physicians marked checkboxes in-
dicating achievement of guideline targets for each risk fac-
tor on the LCP information sheet. In cases where referring 
physicians suspected progression of angina pectoris or oc-
currence of cardiac events, they could immediately consult 
cardiologists in our hospital at any time. Cardiologists in 
our hospital provided information on the results of follow-
up examinations and suggestions for suitable medications to 
referring physicians.
Subjects and data collection
The subjects in this study were a consecutive series of 318 
patients with CAD undergoing PCI from September 2007 
to June 2010 who received outpatient treatment in general 
clinics with LCP after discharge. In addition, as a control, 
we surveyed 140 consecutive patients with CAD undergoing 
PCI from January to December in 2006 who received out-
patient treatment in general clinics before the establishment 
of LCP. The data were collected by retrospectively review-
ing all individual medical records during hospitalization and 
follow-up visits. The first and second visits were scheduled 
at 6 ± 3 months and 12 ± 3 months after hospital discharge, 
respectively. The data collected included body mass index 
(BMI),  blood  pressure,  prescription  of  several  classes  of 
medicines including anti-platelet agents, statins, β-blockers, 
angiotensin-converting enzyme inhibitors (ACE-Is) or an-
giotensin II type I receptor blockers (ARBs), and calcium 
channel blockers (CCBs), and circulating levels of various 
parameters including total cholesterol, triglycerides, high-
density lipoprotein cholesterol (HDL-C), low-density lipo-
protein cholesterol (LDL-C), and HbA1c. This study was 
approved by the Ethics Committee of Kure Medical Center. 
Laboratory measurements
Venous blood was drawn from all of the subjects after an 
overnight  fast.  The  serum  was  immediately  subjected  to 
laboratory  measurements.  Serum  concentrations  of  total 
cholesterol, triglycerides, and HDL-C were determined by 
enzymatic methods (Sekisui Medical Co., Tokyo). The con-
centration of HbA1c (JDS: Japan Diabetic Society) was mea-
sured by high performance liquid chromatography (TOSOH 
Co.,  Tokyo)  and  then  was  calculated  as  HbA1c  (NGSP: 
National  Glycohemoglobin  Standardization  Program)  [8]. 
LDL-C was calculated by the Friedewald formula. 
Achievement of guideline targets for cardiovascular risk 
factors
We used the following targets for management of cardiovas-
cular risk factors in patients with CAD, according to Japa-
nese guidelines [2, 3, 8-11]: BMI < 25 kg/m2, blood pressure 
< 130/80 mmHg, triglycerides < 150 mg/dL, HbA1c (NGSP) 
< 7.0 %, LDL-C < 100 mg/dL, and HDL-C ≥ 40 mg/dL.
Figure 2. Achievement rates of guideline targets for cardiovascular risk factors in clinical practice with liaison critical path. 
Proportions of the patients who achieved body mass index (BMI) < 25 kg/m2, blood pressure (BP) < 130/80 mmHg, tri-
glycerides (TG) < 150 mg/dL, HbA1c < 7.0 %, low density lipoprotein cholesterol (LDL-C) < 100 mg/dL, and high density 
lipoprotein cholesterol (HDL-C) ≥ 40 mg/dL are shown at indicated times. Six-month (6M) and 12-month (12M) visits were 
scheduled at 6 ± 3 months and 12 ± 3 months after hospital discharge, respectively. Statistical analyses were performed 
by chi-square test. #: P < 0.05 vs. before discharge.
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Statistical analysis
Data  are  expressed  as  mean  ±  SEM.  Paired  t-tests  were 
performed to evaluate changes in various parameters after 
hospital  discharge.  The  chi-square  test  was  performed  to 
assess implementation of scheduled visits, cardioprotective 
Figure 3. Changes of several parameters associated with risk factors in clinical practice with liaison critical path. Body 
mass index (BMI) (kg/m2) (A), triglycerides (mg/dL) (B), high density lipoprotein cholesterol (HDL-C) (mg/dL) (C), low 
density lipoprotein cholesterol LDL-C (mg/dL) (D), and HbA1c (%) (E) are shown at indicated times. Six-month (6M) and 
12-month (12M) visits were scheduled at 6 ± 3 months and 12 ± 3 months after hospital discharge, respectively. Data 
are expressed as mean ± SEM. Statistical analyses were performed by paired t-test. **: P < 0.001, *: P < 0.01 vs. before 
discharge.
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medications, achievement of guideline targets for risk fac-
tors, and comparison of medical management between car-
diologists and non-cardiologists. All statistical analyses were 
performed using JMP for Windows software (version 8; SAS 
Institute, Cary, NC). Statistical significance was defined as a 
P value of < 0.05.
 
Results
Implementation of scheduled follow-up visits after hos-
pital discharge
There was no significant difference in the baseline character-
istics of the patients between before and after establishment 
of LCP, except HbA1c (Table 1). Table 2 shows the propor-
tion of patients who implemented the hospital visits sched-
uled at 6 and 12 months after discharge, which significantly 
increased from 50.7% to 89.3% after establishing LCP. 
Among the patients managed with LCP, 10.7% did not 
visit our hospital at 12 months after discharge, which includ-
ed the 6.6% of patients who gave up the scheduled hospi-
tal visits for unavoidable reasons, such as death, muscular 
neurological disorders, and advanced cancers. Only 4.1% of 
patients did not implement scheduled visits for other reasons, 
such as low compliance (data not shown). 
Cardioprotective  medications  in  clinical  practice  with 
LCP
Initial  prescription  rates  for  anti-platelet  agents,  statins, 
β-blockers, and ACE-Is or ARBs were very high (100.0%, 
97.8%, 80.8%, and 76.4% on discharge, respectively). This 
high prescription rate was maintained during the follow-up 
period (99.7%, 95.0%, 77.1%, and 74.3% at the 12-month 
visit, respectively; Fig. 1). The prescription rate for CCBs 
increased from 23.6% on discharge to 32.3% and 31.7% at 
the 6- and 12-month visits, respectively (both P < 0.05 vs. on 
discharge; Fig. 1). 
Achievement of guideline targets for risk factors in clini-
cal practice with LCP
The achievement rate for LDL-C < 100 mg/dL showed a sig-
Table 3. Management of Coronary Artery Disease Patients by Cardiologists and Non-Cardiologists With Liaison 
Critical Path
# Statistical analyses were performed by chi-square test. BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low density lipoprotein cholesterol.
　
　
Cardiologist Non-cardiologist
P#
(n = 45) (n = 74)
Implementation of scheduled visit
6-month visit, (%) 86.2  89.4  0.386 
12-month visit, (%) 85.4  92.0  0.060 
Achievement of targets (12-month)
BMI < 25 kg/m2, (%) 72.1  66.3  0.307 
Blood pressure < 130/80 mmHg, (%) 51.4  55.7  0.482 
Triglycerides < 150 mg/dL, (%) 80.0  80.8  0.865 
HDL-C ≥ 40 mg/dL, (%) 80.8  83.9  0.503 
LDL-C < 100 mg/dL, (%) 69.2  61.3  0.185 
HbA1c < 7.0 %, (%) 88.8  81.8  0.123 
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nificant increase from 48.6% before discharge to 64.5% at 
the 12-month visit (P < 0.05), and that for HDL-C ≥ 40 mg/
dL also significantly increased from 62.0% before discharge 
to 82.7% at the 12-month visit (P < 0.05; Fig. 2). Achieve-
ment rates for triglycerides < 150 mg/dL and HbA1c < 7.0% 
were 80.5% and 84.5% at the 12-month visit, respectively; 
these rates were high before discharge and were maintained 
over 1 year (Fig. 2). On the other hand, the achievement rates 
for BMI < 25 kg/m2 and blood pressure < 130/80 mmHg 
were 68.6% and 53.1% at the 12-month visit; these rates 
were not improved during 1 year of observation (Fig. 2). 
Control of cardiovascular risk factors in clinical practice 
with LCP
In the patients who implemented all visits, BMI, LDL-C, 
HDL-C, and triglyceride levels were significantly improved 
over the follow-up period (BMI, P < 0.001; LDL-C, P < 
0.001; HDL-C, P < 0.001; triglycerides, P < 0.01; Fig. 3). 
HbA1c  significantly  decreased  at  the  6-month  visit  (P  < 
0.05), but this was slightly reversed at the 12-month visit 
(Fig. 3). 
Management of CAD patients with LCP by cardiologists 
and non-cardiologists
Next, we compared the management of CAD patients with 
LCP by referring physicians between cardiologists and non-
cardiologists. As shown in Table 3, there was no significant 
difference in the proportion of patients who visited our hos-
pital for follow-up according to the LCP schedule between 
those treated by cardiologists and those treated by non-car-
diologists. Moreover, the achievement rates of the guideline 
targets for risk factors at the 12-month visit did not differ 
significantly  between  cardiologists  and  non-cardiologists 
(Table 3). 
Discussion
  
Our study demonstrates that the proportion of patients imple-
menting follow-up hospital visits was significantly elevated 
after development of an LCP system. The prescription rates 
of cardioprotective medicines including anti-platelet agents, 
statins, ACE-Is or ARBs, and β-blockers were very high on 
discharge after PCI, and these rates were maintained over 1 
year. The proportion of patients who achieved a LDL-C level 
< 100 mg/dL and a HDL-C level ≥ 40 mg/dL was significant-
ly elevated during 1 year of observation. BMI, triglycerides, 
HDL-C, LDL-C, and HbA1c were significantly improved 
in the patients who implemented all visits scheduled by the 
LCP. Moreover, our study demonstrated that there was no 
significant difference in the management of CAD patients 
between  cardiologists  and  non-cardiologists  when  using 
LCP, suggesting that LCP may be an effective way to bridge 
the gap between published evidence-based guidelines and 
routine clinical practice. 
Despite the establishment of evidence-based guidelines, 
prevention therapies are sometimes underused in daily clini-
cal practice [5, 12-14]. Borden, et al. reported that even after 
the publication of the COURAGE trial, prescription rates 
of statins, ACE-Is or ARBs, and β-blockers were 84.7%, 
60.7%, and 75.9%, respectively, for patients after PCI [5]. 
In our study, the prescription rates of these medicines were 
95.0%, 74.3%, and 77.1% at 1 year after PCI, respectively, 
in patients treated by general primary physicians with LCP. 
This suggests that the LCP system may support general pri-
mary physicians to facilitate the implementation of evidence-
based medication for cardiovascular prevention. 
During clinical practice by Japanese general physicians, 
the achievement rates of guideline targets for LDL-C and 
systolic blood pressure have been reported to be 57.1% and 
34.0%, respectively, although the subjects in this study in-
cluded patients without CAD [15]. In our survey, subjects 
managed with LCP showed relatively higher achievement 
rates of guideline targets; those for LDL-C and blood pres-
sure were 64.5%, 53.1%, respectively. This suggests that the 
LCP system may increase the opportunity for general pri-
mary physicians to develop their awareness of the achieve-
ment of guideline targets. Patients who achieve guideline 
targets  show  significantly  less  cardiovascular  events  than 
those who do not [15]. Therefore, it can be expected that the 
LCP system used in the current study may be effective for 
suppression of cardiovascular events, although we did not 
investigate cardiovascular events directly. 
Thus, the LCP system used seems to be effective in the 
implementation of guideline-based strategies for cardiovas-
cular prevention. This may be not only due to sharing of 
medical information between emergency hospitals and gen-
eral clinics but also due to the multidisciplinary education 
on cardiovascular prevention received by the patients. Such 
education helps patients to understand the significance of 
controlling their cardiovascular risk factors, learn about the 
purpose and effects of their medication, and be more moti-
vated to change their lifestyle. In addition, another essential 
component of the LCP system used may be the reminders for 
follow-up hospital visits sent to both the referring physicians 
and the patients before scheduled examinations. In turn, this 
LCP system should increase the opportunity for cardiologists 
who are aware of up-to-date evidence to conduct optimal 
medical control of risk factors. 
Nevertheless,  in  our  study,  the  continuous  control  of 
body weight, blood pressure, and diabetes seemed to be dif-
ficult even when using the LCP system, which suggests that 
continuing a healthy life-style is more difficult for patients 
than merely starting one. Our LCP system seems to be less 
effective for continuous improvements in lifestyle for pa-
tients. Another system is required to continuously motivate 
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patients to maintain a healthy life-style. 
Our study provides suggestive data on the effects of LCP 
but not conclusive evidence, as it was an observational study 
based on retrospective investigation of medical records in a 
single center. To further investigate the effectiveness of LCP 
systems, including effects on prevention of cardiovascular 
events, multi-center prospective studies with larger samples 
are required. 
We live in an aged society, where even high-risk patients 
should be managed in practice by general physicians, rather 
than cardiologists. In addition, implementation of evidence-
based  cardiovascular  prevention  strategies  in  practice  is 
becoming more important. Our data suggest that LCP for 
CAD may have the potential to facilitate implementation of 
evidence-based medicine in practice, although further inves-
tigations are required.
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